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doi:10.1016/j.jmii.2011.11.006Background/Purpose: To date, vancomycin is still the standard treatment for methicillin-
resistant Staphylococcus aureus (MRSA) infections, but minimum inhibitory concentration
(MIC) creep is becoming a major concern. The aims of this study were to investigate trends
in vancomycin use and MIC values over the last decade at our institute and to evaluate the
outcomes of bacteremic patients infected with MRSA isolates with reduced vancomycin
susceptibility.
Methods: Vancomycin use and density were evaluated using the defined daily doses (DDD)
method. Patients with MRSA bacteremia were enrolled retrospectively. Patient demographic
data and clinical outcomes were analyzed. The first isolate from each patient was collected
for E-testing in order to determine vancomycin MIC. MIC trends were assessed as MIC50,
MIC90, and the geometric mean.
Results: Vancomycin use has increased over the last decade. One hundred and forty patients
were enrolled and their respective isolates were retrieved, including isolates from 45 patients
in 2001, 46 patients in 2005, and 49 patients in 2009. The geometric mean ( standard devia-
tion) of the vancomycin MIC for MRSA isolates obtained in 2009 was 1.39  0.30 mg/mL, which is
significantly higher than the mean vancomycin MIC obtained in 2001 (1.19  0.34 mg/mL,
p < 0.01) and 2005 (1.99  0.25 mg/mL, p < 0.001). There were no significant differences in
terms of the in-hospital mortality rate between patients with MRSA isolates with
MICs  1.5 mg/mL or < 1.5 mg/mL.g Lin, Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine,
Defense Medical Center, No. 325 Cheng-Kung Road, Section 2, Nei-hu 114, Taipei, Taiwan.
u.tw (J.-C. Lin).
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Vancomycin MIC creep in bacteremic MRSA 215Conclusion: We identified a significant upward trend in the use of vancomycin and its MIC over
the last decade. This study shows that patients infected with MRSA isolates with high MICs
(1.5 mg/mL) do not have a significantly higher mortality rate compared with isolates with
low MICs (<1.5 mg/mL).
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Staphylococcus aureus is one of the most common patho-
gens that leads to severe infections, including skin and soft
tissue infections, pneumonia, bacteremia, and endocardi-
tis, either in community settings or hospitals. According to
the Taiwan Nosocomial Infections Surveillance (TNIS)
database, the proportion of methicillin-resistant S aureus
(MRSA) isolates among all S aureus isolates in intensive
care units (ICU) is 78.0%.1 Patients with MRSA bacteremia
have a higher mortality rate and must endure longer
hospital stays than those with methicillin-susceptible
S aureus (MSSA) bacteremia.2 Infections caused by MRSA
are worse than those caused by other pathogens due to
the limited choices of antibiotics that are available and the
fact that it is difficult to eradicate these strains. The
relationship between the failure of vancomycin to treat
MRSA and infections has been demonstrated in several
studies; the recent emergence of heterogeneous
vancomycin-intermediate S aureus (hVISA), vancomycin-
intermediate S aureus (VISA), and vancomycin-resistant S
aureus (VRSA) poses additional challenges for vancomycin
therapy.3,4
To date, vancomycin is the conventional and most-used
drug for the treatment of MRSA infections. Several studies
have reported that the increase in the vancomycin
minimum inhibitory concentration (MIC) for treating MRSA
is associated with a substantial risk of vancomycin treat-
ment failure and a higher mortality rate.5e7 Lodise et al
observed that patients with MRSA bloodstream infections
with elevated vancomycin MICs (1.5 mg/mL) had longer
durations of bacteremia, higher probabilities of recurrent
bacteremia within 60 days after vancomycin discontinua-
tion, and longer hospital stays.8 Sakoulas et al reported
that the likelihood of treatment success is significantly
lower in patients with MRSA isolates with a vancomycin
MIC of 1e2 mg/mL compared with patients infected by
isolates with a vancomycin MIC  0.5 mg/mL.9 These
studies concluded that the progressive increase in vanco-
mycin MICs within a susceptible range represents the “MIC
creep” phenomenon that is often associated with MRSA
infections.
In this context, several studies have demonstrated
an increase in vancomycin MICs over the last several
years, but other studies are ambiguous regarding MIC
creep.10e14 Thus, the aim of our study was to evaluate
MIC trends in clinical bacteremic MRSA isolates over the
last decade in our medical center in northern Taiwan
and to compare mortality rates among patients infected
by MRSA during this period with MRSA isolates with
different MICs.Materials and methods
Study design and patients
This retrospective study was conducted at Tri-Service
General Hospital, a 1,700-bed facility serving as a primary
care and tertiary referral center in Taipei, Taiwan. The
annual consumption of parenteral vancomycin in our
hospital, in terms of daily defined doses (DDD) per 1000
patient-days, during 200e2010 were calculated based on
theWorld Health Organization’s definition of 2 g vancomycin
as one DDD.15 A list of patients with MRSA bacteremia in
2001, 2005, and 2009 was retrieved from the hospital’s
clinical microbiology laboratory databases. All of the iden-
tified patients were enrolled, and their medical charts were
reviewed. Clinical information was collected, including age,
sex, co-morbidities, clinical outcomes, and laboratory
information. For patients with several episodes of MRSA
bacteremia, only the first episode was enrolled in this study.
Several risk factors were taken into consideration in the
analysis and are summarized in Table 1. Renal failure was
defined as an elevated serum creatinine level >1.5 mg/dL,
either acute or chronic. Neutropenia was defined as an
absolute neutrophil count <500 neutrophils/mL. Septic
shock was defined as sepsis-induced hypotension (systolic
blood pressure <90 mmHg or diastolic blood pressure
<50 mmHg) that persisted despite adequate fluid resusci-
tation on the day bacteremia was diagnosed. Prior glyco-
peptide use was defined as glycopeptide use for at least 24
hours within the previous 30 days.Microbiological analysis
Only one MRSA isolate per patient was included in the
microbiological portion of this study. All isolates were
identified using routine bacteriological procedures. Methi-
cillin susceptibility testing was performed using the disk
diffusion method, in accordance with the criteria of the
Clinical and Laboratory Standards Institute (CLSI).16 Van-
comycin MIC determination was performed using the Etest
method, according to the manufacturer’s guidelines. A
suspension of saline calibrated to the 0.5-McFarland
turbidity standard was plated onto Mueller-Hinton agar,
onto which Etest strips (AB BIODISK, Solna, Sweden) were
applied. The plates were incubated at 35C for 24 hours.
The MIC was interpreted as the zone of inhibition that
corresponded to a concentration gradient on the Etest
strips, according to the manufacturer’s guidelines. Quality
control was performed using the CLSI-recommended
reference strain (ATCC 29213).16
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Figure 1. Annual intravenous vancomycin usage density,
2003-2010. One daily dose of vancomycin was defined as 2 g.
Table 1 Demographic characteristics, clinical presentation, and clinical outcomes of 140 patients with MRSA bacteremia in
each study year
Year 2001 (n Z 45) 2005 (n Z 46) 2009 (n Z 49) p-value
Age (y) 65.2  17.5 69.1  19.0 72.9  17.8 0.11
Male sex, n (%) 26 (57.8) 35 (76.1) 30 (61.2) 0.15
Co-morbidity, n (%)
Diabetes mellitus 31 (68.9) 28 (60.9) 25 (51.0) 0.21
Surgery within previous 30 d 26 (57.8) 25 (54.4) 19 (38.8) 0.14
Renal failure 14 (31.1) 22 (47.8) 20 (40.8) 0.26
Solid neoplasm 13 (28.9) 6 (13.0) 13 (26.5) 0.148
Congestive heart failure 11 (24.4) 11 (23.9) 8 (16.3) 0.56
Dementia 5 (11.1) 8 (17.4) 12 (24.5) 0.24
Neutropenia 5 (11.1) 2 (4.4) 2 (4.1) 0.30
Hematological neoplasm 5 (11.1) 0 (0.0) 4 (8.2) 0.08
Chronic obstructive Pulmonary disease 3 (6.7) 8 (17.4) 3 (6.1) 0.13
Valvular heart disease 3 (6.4) 7 (15.2) 5 (10.2) 0.42
Alcoholism 2 (4.4) 1 (2.2) 2 (4.1) 0.82
Liver cirrhosis 2 (4.4) 3 (6.5) 5 (10.2) 0.55
Community-onset infection 20 (44.4) 14 (30.4) 24 (49.0) 0.16
Receipt of empirical glycopeptide 18 (40.0) 17 (37.0) 20 (40.8) 0.92
Glycopeptide use within previous 30 d 4 (8.9) 9 (19.6) 15 (30.6) 0.03
Septic shock 22 (48.9) 20 (43.5) 22 (44.9) 0.89
In-hospital mortality 19 (42.2) 16 (34.8) 22 (44.9) 0.59
216 Y.-C. Yeh et al.Statistical analysis
Comparisons of the contingency data obtained for each
study group were carried out using the c2 test or the
Fisher’s exact test, while comparisons of continuous data
were performed using one-way analysis of variation
(ANOVA) or the Student t test. Variables with two-tailed
p < 0.05 were considered statistically significant. Pear-
son’s c2 test was used for comparisons of vancomycin usage
in our hospital. In order to identify the risk factors associ-
ated with mortality, univariate analysis was first con-
ducted. Variables with a p < 0.05 were then analyzed using
multivariate analysis. All analyses were performed using
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).
Results
The annual consumption of parenteral vancomycin in our
hospital (in terms of DDD per 1000 patient-days) was 9.06 in
2003, 9.22 in 2004, 10.92 in 2005, 9.50 in 2006, 9.86 in 2007,
9.85 in 2008, 13.47 in 2009, and 13.05 in 2010. Fig. 1 shows
the increase in annual intravenous vancomycin use density
from 2003e2010 (earlier data could not be obtained due to
a shift in the hospital information system). The annual
consumption of parenteral vancomycin in our hospital was
10.92 in 2005 and 13.47 in 2009, a statistically significant
difference (p Z 0.001).
During the study years, a total of 140 patients with
MRSA bacteremia were enrolled for analysis, including
45 patients in 2001, 46 in 2005, and 49 in 2009. The
demographic and clinical characteristics of these patients
are summarized in Table 1. The mean age was 65.2  17.5
years in 2001, 69.1  19.0 in 2005, and 72.9  17.8 in 2009.The percentage of male patients that were treated was
57.8% in 2001, 76.1% in 2005, and 61.2% in 2009.
The use of intravascular catheters in this study included
37 cases of central venous catheters, 17 cases of double
lumen catheters, and 6 cases of Swan-Ganz catheters. All
cases of neutropenia resulted from sepsis; none were
related to postchemotherapy neutropenia. Surgery within
the first 30 days was defined as a major surgery if either
general or local anesthesia was used; this mainly included
13 surgeries for debridement, 10 for percutaneous creation
of arteriovenous shunts, 9 for tracheostomy, and 4 for
Hickman catheter implantation. Empirical glycopeptides
Figure 2. Percentage of 140 bacteremic MRSA isolates with
different vancomycin MICs.
Vancomycin MIC creep in bacteremic MRSA 217were used in 55 of the 140 episodes of MRSA bacteremia,
including 45 uses of vancomycin. There were no significant
differences across the 3 years of this study in terms of
patient age, sex, co-morbidities, community-acquired
infections, empirical glycopeptides use, septic shock, or in-
hospital mortality.
All 140 documented S aureus strains were susceptible to
vancomycin, exhibiting MICs below the current CLSI
breakpoint (2 mg/mL).16 The vancomycin MICs for each
study year are shown in Fig. 2. A decrease was observed in
the number of strains with MICs < 1.5 mg/mL (57.8% in 2001
vs. 28.6% in 2009); a complementary increase was noted for
the number of strains with MICs  1.5 mg/mL (42.22% in
2001 vs. 71.43% in 2009).
The MIC50 among blood isolates in 2009 was 1.5 mg/mL,
while an MIC50 of 1.0 mg/mL among blood isolates was found
in 2001 and 2005. The MIC90 among blood isolates across the
entire 3 years of this study was 1.5 mg/mL. The geometric
means  standard deviations for the vancomycin MICs were
1.19  0.34 mg/mL in 2001, 0.99  0.27 mg/mL in 2005, and
1.39  0.30 mg/mL in 2009, with the last year exhibiting
a significant increase compared with 2001 (p Z 0.008) and
2005 (p < 0.001). Statistics for MRSA vancomycin MIC
obtained for each study interval, including the geometric
mean, MIC50, and MIC90, are shown in Table 2. Vancomycin
MICs demonstrated a clear shift over the course of this
study.
Comparisons of the clinical features and outcomes
between the low (< 1.5 mg/mL) and high ( 1.5 mg/mL)
vancomycin MIC groups, and between death and survival
rates (i.e., in-hospital mortality), are shown in Table 3. We
found that patients infected with strains with elevated MICs
( 1.5 mg/mL) were strongly associated with the initial
presentation of septic shock (p < 0.05) and the use ofTable 2 Statistics on MRSA-vancomycin MICs for each year stud
Year Number of
strains
MIC50
(mg/mL)
MIC90
(mg/mL)
MIC <
n (%)
2001 45 1 1.5 26 (57
2005 46 1 1.5 38 (82
2009 49 1.5 1.5 14 (28
MIC: minimum inhibitory concentration.glycopeptides within the 30 days preceding the isolation of
a positive culture (p Z 0.02). Comparisons of the in-
hospital mortality rates among patients harboring isolates
with different MICs revealed no significant differences
(p Z 0.54).
Univariate analysis determined that the use of an
intravascular catheter (p Z 0.01) and septic shock
(p < 0.05) are risk factors for in-hospital mortality. Multi-
variate analysis determined that septic shock is the only
independent factor associated with MRSA bacteremia (OR,
25.75; 95% CI: 8.36e79.33). All statistical results are shown
in Table 4.
Discussion
In this study, we calculated the vancomycin usage density
(in terms of DDD) per 1000 patient-days; this parameter
revealed an increase in the usage density, especially in
2009e2010. We observed a shift in the MICs of vancomycin
over the same interval. Our results contrast those of Alos
et al, who reported no vancomycin MIC creep from
2002e2006 in a setting with a low usage of vancomycin
(Spain); no increase in vancomycin density was found in the
years of their study.13 Due to the recent discovery of
decreased clinical efficacy and therapeutic response to
vancomycin, the Infectious Diseases Society of America
(IDSA) recommended an adjustment in the target vanco-
mycin trough level to 15e20 mg/mL for serious MRSA
infections in 2009.17,18 This could be the reason why the
vancomycin usage density increased in our hospital.
Most surveillance studies have recently reported
changes in vancomycin susceptibility10e12,19; however,
some studies examining vancomycin MIC creep in MRSA
isolates have shown inconsistent results.13,14 In this study,
we demonstrated the existence of the vancomycin creep
phenomenon for bacteremic MRSA isolates in our hospital
across 3 years (2001, 2005, and 2009). We used the Etest
method to determine vancomycin MICs and also employed
frequency distributions and geometric mean analyses to
demonstrate shifts in vancomycin MICs in MRSA blood
isolates. Our data demonstrate a clear and significant
difference in vancomycin MICs in our hospital across the
3 years that were studied. There are several other studies
that investigated this MIC creep phenomenon, some of
which are consistent with our observations.10e12,19 A
20-year study conducted in a large French teaching hospital
demonstrated decreased susceptibility to glycopeptides in
MRSA.19 Steinkraus et al reported that the MICs for
oxacillin, vancomycin, and linezolid increased in clinical
MRSA isolates from 2001e2005 at a tertiary care institutionied
1.5 mg/mL, MIC  1.5 mg/mL,
n (%)
Geometric mean
(mg/mL)
.8) 19 (42.2) 1.19  0.34
.6) 8 (17.4) 0.99  0.27
.6) 35 (71.4) 1.39  0.30
Table 3 Comparisons of clinical features and outcomes between low (<1.5 mg/mL) and high (1.5 mg/mL) vancomycin MIC
groups and comparisons between death and survival (in-hospital mortality)
Low MIC High MIC p-value In-hospital mortality p-value
(<1.5 mg/mL) (1.5 mg/mL) Survival Death
(n Z 78) (n Z 62) (n Z 83) (n Z 57)
Male sex, n (%) 51 (65.4) 40 (64.5) 1 53 (63.9) 38 (66.7) 0.73
Age, mean y  SD 68.4  18.2 70.2  17.3 0.55 68.3  17.9 70.5  17.7 0.46
Co-morbidity, n (%)
Intravascular catheter 40 (51.3) 40 (65.4) 0.12 40 (48.2) 40 (70.2) 0.01
Surgery within previous 30 d 37 (47.4) 33 (53.2) 0.61 44 (53) 26 (45.6) 0.39
Diabetes mellitus 34 (43.6) 33 (53.2) 0.31 45 (54.2) 22 (38.6) 0.69
Renal failure 31 (39.7) 25 (40.3) 1 33 (39.8) 23 (40.4) 0.94
Valvular heart disease 10 (12.8) 5 (8.1) 0.42 6 (7.2) 9 (15.8) 0.11
Heart failure 17 (21.8) 13 (21.0) 1 14 (16.9) 16 (28.1) 0.11
Solid neoplasma 17 (21.8) 15 (24.2) 0.84 16 (19.3) 16 (28.1) 0.22
Chronic obstructive pulmonary disease 10 (12.8) 4 (6.5) 0.26 11 (13.3) 3 (5.3) 0.12
Dementia 9 (11.5) 16 (25.8) 0.04 17 (20.5) 8 (14) 0.32
Liver cirrhosis 8 (10.3) 2 (3.2) 0.19 5 (6) 5 (8.8) 0.19
Hematological neoplasma 3 (3.8) 6 (9.7) 0.18 3 (3.6) 6 (10.5) 0.1
Alcoholism 2 (2.6) 3 (4.8) 0.66 2 (2.4) 3 (5.3) 0.37
Bone marrow transplantation 0 (0.0) 2 (3.2) 0.19 2 (2.4) 0 (0) 0.24
Glycopeptide use within previous 30 d 10 (12.8) 18 (29.0) 0.02 69 (83.1) 43 (75.4) 0.26
Septic shock 30 (38.5) 34 (54.8) <0.05 17 (20.5) 47 (82.5) <0.05
In-hospital mortality 30(38.7) 27(43.55) 0.54
MIC S 1.5 mg/mL 35 (42.17) 27 (47.37) 0.54
MIC: minimum inhibitory concentration.
218 Y.-C. Yeh et al.in the USA. 10 In another recent study, Ho et al reported
vancomycin MIC creep among MRSA isolates in a region of
Hong Kong from 1997e2008.12 However, in another study,
the SENTRY Antimicrobial Surveillance Program reported noTable 4 Factors independently associated with mortality
as determined using a logistical regression model of patients
with MRSA bacteremia
Factor OR (95% CI) p-value
Diabetes melllitus 0.48 (0.15e1.54) 0.22
Valvular heart disease 2.13 (0.34e13.38) 0.42
Surgery within previous 30 d 0.60 (0.22e1.64) 0.32
Alcoholism 0.96 (0.09e10.43) 0.97
Dementia 0.29 (0.07e1.16) 0.08
Liver cirrhosis 1.77 (0.32e9.93) 0.52
Heart failure 1.09 (0.25e4.76) 0.91
Renal failure 0.64 (0.20e4.76) 0.46
Chronic obstructive
pulmonary disease
0.98 (0.17e5.53) 0.98
Solid neoplasm 1.69 (0.53e5.34) 0.37
Hematologic neoplasm 3.02 (0.21e43.58) 0.42
Prior glycopeptides
use in 30 d
0.42 (0.10e1.69) 0.22
Intravascular catheter 0.40 (0.14e1.16) 0.09
Septic shock 25.75 (8.36e79.33) <0.05
MIC S 1.5 mg/mL 0.87 (0.50e1.51) 0.62
MIC: minimum inhibitory concentration; OR: odds ratio;
CI: confidence interval.evidence of increased vancomycin resistance during
1998e2003 when vancomycin MICs were analyzed.20 Musta
et al demonstrated that the vancomycin MIC distribution
was stable over an 11-year span from 1996e2006.21 Kehr-
mann et al examined bloodstream MRSA isolates at several
hospitals in two German cities between 2004e2009. That
study concluded that the creep phenomenon seems to vary
by region.14 Different observations in these vancomycin MIC
creep-associated studies may be due to differences in the
study periods, geographic locations, vancomycin usage
densities, number of enrolled cases, and MIC assays that
were employed (e.g., Etest, microdilution, or automated
methods).
For the primary outcome analysis, we compared the
initial clinical presentation (e.g., shock) and clinical
outcome (i.e., in-hospital mortality) between low
(<1.5 mg/mL) and high ( 1.5 mg/mL) MIC isolates. Our
results are similar to those of Lodise et al, who reported no
significant difference in mortality,8 and Soriano et al, who
noted that a higher MIC does not correlate with a higher
probability of a patient going into shock. In contrast, Wang
et al reported higher mortality rates among patients
infected with MRSA strains with elevated MICs,7 which is not
consistent with our observations. Among the present
study’s patients who had used glycopeptides during the
preceding 30 days, a larger proportion of patients were
infected with isolates with high ( 1.5 mg/mL) MICs
(p Z 0.017), as noted by Lodise et al.22 Indeed, patients
with MRSA bacteremia who have been recently treated with
vancomycin are known to exhibit reduced susceptibility to
this antibiotic, and alternative therapy is recommended for
Vancomycin MIC creep in bacteremic MRSA 219such individuals if an optimal treatment response is not
obtained.
Our study has some limitations. First, this was a retro-
spective and single-center study, and we did not analyze
clonal transmission patterns among MRSA isolates; we did
not know the exact clonal prevalence or changes that
occurred over time at our local institution. Second, for the
comparison of clinical outcomes and MIC, we included only
in-hospital mortality and excluded microbiologic failure
and recurrence after anti-MRSA treatment. While this
approach is consistent with the work of Lodise et al,8 we
did not observe the same influence on higher MIC levels as
that analysis. Third, we used the Etest method, rather than
the broth microdilution method, to determine vancomycin
MICs; the two techniques have been reported to yield MIC
values that differ by up to two-fold.23 Fourth, the vanco-
mycin trough level of each MRSA infection could not be
retrieved in our study. Vancomycin therapeutic guidelines
from IDSA recommended keeping trough serum vancomycin
concentrations at 15e20 mg/mL in order to achieve a tar-
geted AUC/MIC > 400 for most patients, assuming the MIC
is < 1 mg/mL.18 That might be the reason why we couldn’t
determine the influence of higher vancomycin MICs on
mortality in this study.
In conclusion, we detected the occurrence of the van-
comycin MIC creep phenomenon in our hospital during three
study periods. This event overlapped with an increase in
the vancomycin usage density (in terms of DDD per 1000
patient-days), which rose from 2003e2010. Our study also
observed that vancomycin usage in the 30 days prior to
isolation of a positive culture did positively correlate with
higher MICs; in addition, we did not observe an increase in
in-hospital mortality among patients infected with higher-
MIC isolates. Septic shock was the only independent factor
associated with in-hospital mortality, as determined by
multivariate analysis. Similar to IDSA’s recommendation for
the treatment of MRSA infections,17 we suggest continued
vancomycin use to treat MRSA infections if the vancomycin
MIC is below 2 mg/mL, while alternative treatments should
be considered if a clinical or microbiologic response to
vancomycin is not achieved. All medical institutions should
monitor their local vancomycin MICs for MRSA isolates in
order to help understand resistance among Staphylococcus
species that is now commonplace.Acknowledgments
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